- Home
- GHRS vs CHY Comparison
GHRS vs CHY Comparison
Compare GHRS & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- CHY
- Stock Information
- Founded
- GHRS 2018
- CHY 2003
- Country
- GHRS Ireland
- CHY United States
- Employees
- GHRS N/A
- CHY N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- GHRS Health Care
- CHY Finance
- Exchange
- GHRS Nasdaq
- CHY Nasdaq
- Market Cap
- GHRS 868.7M
- CHY 760.9M
- IPO Year
- GHRS 2021
- CHY N/A
- Fundamental
- Price
- GHRS $9.10
- CHY $9.87
- Analyst Decision
- GHRS Strong Buy
- CHY
- Analyst Count
- GHRS 7
- CHY 0
- Target Price
- GHRS $30.86
- CHY N/A
- AVG Volume (30 Days)
- GHRS 208.9K
- CHY 128.3K
- Earning Date
- GHRS 05-02-2025
- CHY 01-01-0001
- Dividend Yield
- GHRS N/A
- CHY 10.11%
- EPS Growth
- GHRS N/A
- CHY N/A
- EPS
- GHRS N/A
- CHY N/A
- Revenue
- GHRS N/A
- CHY N/A
- Revenue This Year
- GHRS N/A
- CHY N/A
- Revenue Next Year
- GHRS N/A
- CHY N/A
- P/E Ratio
- GHRS N/A
- CHY N/A
- Revenue Growth
- GHRS N/A
- CHY N/A
- 52 Week Low
- GHRS $6.00
- CHY $9.97
- 52 Week High
- GHRS $20.50
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- GHRS 39.47
- CHY 45.28
- Support Level
- GHRS $8.51
- CHY $9.66
- Resistance Level
- GHRS $9.36
- CHY $9.99
- Average True Range (ATR)
- GHRS 0.79
- CHY 0.31
- MACD
- GHRS -0.11
- CHY 0.03
- Stochastic Oscillator
- GHRS 33.94
- CHY 68.75
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.